Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.
about
Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cellsCloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IVQnrS1 structure-activity relationships.Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumanniiRole of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.Broad-host-range gyrase A gene probe.Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacinDose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrAPersistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones.nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.Ofloxacin resistance mechanism in PA150 and PA300-clinical isolates of Pseudomonas aeruginosa in Korea.
P2860
Q24676018-3DE84C7B-7F7D-48FC-B146-22DCC9141A24Q28492734-AD281A57-E967-4CEA-B7DC-8160D2388B92Q33909989-4066AEED-0E6B-4FA4-95C8-304C37BC6C04Q35111809-5246FC4E-99C4-4CF2-9DE0-084E74D74FEAQ35114895-1B159E0E-A2E9-4AA7-B84A-638A23BDCB57Q35119495-6ABC4EC0-5D1D-4A09-9F9E-64FBCB8C7962Q35276491-FD7887AB-BFD6-4EA1-8FB2-AA7EA72740DDQ35598576-4794F355-4BF2-43C5-8962-0FC1F53F127DQ35818681-AA19EC4F-1FF1-490B-A736-7CA1620A4686Q35836280-C338EC13-EC16-43B3-9068-82A91779798BQ35893473-6B24187A-3422-4F5D-BBDC-C19376EA618EQ36752823-52B1143E-9AB2-41BF-9945-A71CB2530BC7Q36753750-98ACE4D0-F29F-4630-83AE-AA04BCBE877BQ36754434-2606B5BE-3BAB-4C9D-875B-08F99C22E6DBQ36755663-3251E6E1-18C1-4E59-9B28-5FCF4FA3EC5CQ36758128-0DA4C00F-BB75-46BD-A2AD-6C5B4DF16ED5Q39779448-2CCD7785-37EA-47D8-BF7A-080FADA9DFF2Q40088314-1160F404-7D85-4C59-B4F7-810B461942D6Q40284197-96ED8156-36FA-4F07-B49B-3CE9043CB045Q40633555-9AE3CDF3-5581-434D-A295-697A6E420AD2Q54111093-27AC220E-A8DD-445B-9266-33521A3C2525
P2860
Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.
description
1990 nî lūn-bûn
@nan
1990 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Analysis of acquired ciproflox ...... ain of Pseudomonas aeruginosa.
@ast
Analysis of acquired ciproflox ...... ain of Pseudomonas aeruginosa.
@en
type
label
Analysis of acquired ciproflox ...... ain of Pseudomonas aeruginosa.
@ast
Analysis of acquired ciproflox ...... ain of Pseudomonas aeruginosa.
@en
prefLabel
Analysis of acquired ciproflox ...... ain of Pseudomonas aeruginosa.
@ast
Analysis of acquired ciproflox ...... ain of Pseudomonas aeruginosa.
@en
P2093
P2860
P356
P1476
Analysis of acquired ciproflox ...... ain of Pseudomonas aeruginosa.
@en
P2093
Masecar BL
Robillard NJ
P2860
P304
P356
10.1128/AAC.34.2.281
P407
P577
1990-02-01T00:00:00Z